Email this article mRNA-based therapeutics–Advances and perspectives
- Authors: Sergeeva O.V.1,2, Koteliansky V.E.1,2, Zatsepin T.S.1,2,3
-
Affiliations:
- Department of Chemistry
- Skolkovo Innovation Center
- The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance
- Issue: Vol 81, No 7 (2016)
- Pages: 709-722
- Section: Review
- URL: https://journals.rcsi.science/0006-2979/article/view/150939
- DOI: https://doi.org/10.1134/S0006297916070075
- ID: 150939
Cite item
Open Access
Access granted
Subscription Access
Abstract
In this review we discuss features of mRNA synthesis and modifications used to minimize immune response and prolong efficiency of the translation process in vivo. Considerable attention is given to the use of liposomes and nanoparticles containing lipids and polymers for the mRNA delivery. Finally we briefly discuss mRNAs which are currently in the clinical trials for cancer immunotherapy, vaccination against infectious diseases, and replacement therapy.
Keywords
About the authors
O. V. Sergeeva
Department of Chemistry; Skolkovo Innovation Center
Author for correspondence.
Email: olga.sergeeva.v@gmail.com
Russian Federation, Moscow, 119991; 3 Nobel str., Moscow, 143026
V. E. Koteliansky
Department of Chemistry; Skolkovo Innovation Center
Email: olga.sergeeva.v@gmail.com
Russian Federation, Moscow, 119991; 3 Nobel str., Moscow, 143026
T. S. Zatsepin
Department of Chemistry; Skolkovo Innovation Center; The Federal Service on Customers’ Rights Protection and Human Well-being Surveillance
Email: olga.sergeeva.v@gmail.com
Russian Federation, Moscow, 119991; 3 Nobel str., Moscow, 143026; Moscow, 111123
